Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 129 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Liver Transplant Recipients Clear all

Conditions: Living Donor Liver Transplantation
Interventions: Donor-derived DCreg; Biological
Lead sponsor: Angus W. Thomson PhD DSc; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Liver Transplant Recipients
Interventions: Not listed
Lead sponsor: Baylor Research Institute; Other
Eligibility: 17 Years to 65 Years
Enrollment: 221 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2013
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Kidney Transplant, Liver Transplant
Interventions: Letermovir; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Medication Adherence, Liver Transplant Disorder
Interventions: Praise Text Messages; Behavioral
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 13 Years to 21 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Liver Failure
Interventions: Anti-Thymocyte Globulin, ATG (Rabbit), Total lymphoid irradiation; Drug · Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Stanford, California

Conditions: Evidence of Liver Transplantation
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Chronic Hepatitis C, Organ Transplantation, Immunosuppression
Interventions: Neoral, Tacrolimus; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Liver Transplant Recipients
Interventions: Cozaar; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 62 participants
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pediatric Recipients of a Liver Transplant
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 1 Year to 18 Years
Enrollment: 401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 5
States / cities: Los Angeles, California • Chicago, Illinois • New York, New York + 2 more

Conditions: Liver Transplantation
Interventions: Sirolimus (Rapamune), Cyclosporine or Tacrolimus; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 13 Years and older
Enrollment: 607 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 10
States / cities: San Francisco, California • Tampa, Florida • New Orleans, Louisiana + 7 more

Conditions: Kidney Transplantation, Hepatitis C
Interventions: sofosbuvir/velpatasvir; Drug
Lead sponsor: Amit D Tevar, MD; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HIV, Awaiting Organ Transplant
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Immunosuppression
Interventions: Myfortic; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Kidney Disease, Liver Transplantation
Interventions: Not listed
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Liver Transplantation
Interventions: Tacrolimus (reduced tacrolimus), Tacrolimus (tacrolimus elimination), Tacrolimus (tacrolimus control), Everolimus (reduced tacrolimus), Everolimus (tacrolimus elimination), Corticosteroids; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 719 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 28
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 20 more

Conditions: Liver Transplant Recipient, Living Donor (of the Respective Liver Transplant Recipient)
Interventions: darTregs, Acetaminophen, Diphenhydramine, Immunosuppression (IS) Withdrawal, Study Mandated Procedures; Biological · Drug · Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: San Francisco, California • Chicago, Illinois • Rochester, Minnesota

Conditions: Cervical Cancer, Hpv, Warts
Interventions: Quadrivalent HPV for types 6, 11, 16 and 18; Biological
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 9 Years to 17 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: Hepatitis C Infection
Interventions: ITX 5061; Drug
Lead sponsor: Schiano, Thomas D., MD; Other
Eligibility: 18 Years to 72 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis C
Interventions: Mavyret; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Liver Transplant, Hepatitis C, Chronic Kidney Disease, Acute Rejection
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2031
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pediatric Liver Transplantation
Interventions: Corticosteroids, Cyclosporine, mycophenolate mofetil; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 3 Months to 12 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 2
States / cities: San Francisco, California • New York, New York

Conditions: GI Disturbance
Interventions: Mycophenolic Acid (Myfortic); Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hepatitis B, Liver Transplantation
Interventions: Adefovir dipivoxil and hepatitis B vaccination; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Kidney Transplant, Hepatitis C, HCV
Interventions: Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

Delayed Infusion of DCreg in Living Donor Liver Transplantation

Blood Draw Study for Liver Transplant Patients

Letermovir for R+ Study

Text Messages for Liver Transplant Recipients

TLI- and ATG-Enabled Minimization Protocol in Liver Transplantation

Cefepime Pharmacokinetics in Liver Transplant Recipients in an Intensive Care Unit

Randomized Controlled Trial in Liver Transplant Recipients Treated in Steroid Sparing Regimen

The Effects of Angiotensin II Receptor Blockade on Kidney Function and Scarring After Liver Transplant

Medication Adherence in Children Who Had a Liver Transplant

Study Evaluating of Calcineurin Inhibitor and Sirolimus (Rapamune) Treatment in Liver Transplant Recipients

The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients

Observational Study of Solid Organ Transplantation Utilizing HIV-Positive Donors in HIV-Positive Recipients

Conversion of CellCept to Myfortic: A Prospective Study in Liver Transplant Recipients

Evaluation of Kidney Disease in Liver Transplant Recipients

Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients

Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction

Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?

Study of Hepatitis C Virus (HCV) Entry Inhibitor in Liver Transplant Recipients With HCV Infection

A Study of the Use of Hepatitis C Positive Donors for Hepatitis C Negative Lung Transplant Recipients With Post-transplant Treatment With Mavyret

Proteogenomic Monitoring and Assessment of Liver Transplant Recipients

Safety, Tolerability and Pharmacokinetics of Oral CellCept (Mycophenolate Mofetil) in Pediatric Liver Transplant Recipients on Concomitant Treatment With Cyclosporine and Corticosteroids

Myfortic Conversion Trial in OLT Recipients With GI Intolerance

Adefovir Plus Vaccination in Transplant Patients Without Hepatitis B That Receive a Core Antibody Positive Liver

Utilization of Hepatitis C Positive Kidneys in Negative Recipients